Plasma-Diluted Thrombin Time to Measure Dabigatran Concentrations During Dabigatran Etexilate Therapy
Open Access
- 1 April 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 137 (4), 572-574
- https://doi.org/10.1309/ajcpau7oqm0srpzq
Abstract
New anticoagulants, like the orally available direct thrombin inhibitor (DTI) dabigatran etexilate, have recently been introduced into the market forKeywords
This publication has 5 references indexed in Scilit:
- Dabigatran: An Oral Novel Potent Reversible Nonpeptide Inhibitor of ThrombinArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activityThrombosis and Haemostasis, 2010
- Pharmacology, Pharmacokinetics, and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin InhibitorClinical and Applied Thrombosis/hemostasis, 2009
- The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjectsBritish Journal of Clinical Pharmacology, 2007
- Monitoring direct thrombin inhibitors with a plasma diluted thrombin timeThrombosis and Haemostasis, 2007